Novel method for regulating immune effect of mesenchymal stem cells

MSCs are pretreated by modulating drug nanoparticles through interferon-carrying pathway, combined with Chinese medicine active monomers and gene silencing technology, and the problem of insufficient immunosuppressive ability of MSCs in severe acute pancreatitis is solved, significantly improving its immunosuppressive effect and reducing it The risk of transplant rejection is provided, and new treatment ideas are provided.

CN118903202APending Publication Date: 2024-11-08SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310499718.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Mesenchymal stem cells (MSCs) lack effective immunosuppressive mechanisms in the intervention of severe acute pancreatitis, and the prior art is difficult to meet clinical treatment requirements, and unpretreated MSCs lack immunomodulatory effects under inflammatory conditions.

Method used

Pretreatment of MSCs through the interferon-carrying pathway to regulate drug nanoparticles/liposomes, enhance their immunosuppressive effects, combine IFN-γ and Chinese medicine active monomers such as rhubarb anthraquinones to promote the immunosuppressive function of MSCs, and through Gene silencing techniques reduce HLA-II expression to avoid immune rejection.

Benefits of technology

It significantly enhances the immunosuppressive ability of MSCs, reduces the inflammatory state of severe acute pancreatitis, improves the activation inhibitory effect of CD4+ T cells, and reduces the risk of cell proliferation and transplant rejection, providing new treatment ideas and methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and relates to a novel method for regulating immunosuppressive activity of mesenchymal stem cells and application of the novel method. The mesenchymal stem cells are pretreated at least through IFN-gamma in combination with a traditional Chinese medicine monomer with anti-inflammatory activity, such as aloe-emodin, so that the immunity inhibition activity of the mesenchymal stem cells is improved. The effect is mainly realized by promoting expression of immunocompetence molecules related to mesenchymal stem cells, including IDO, PD-L1 and the like, and the aloe-emodin is mainly used for enhancing the effect of the aloe-emodin by regulating a classical interferon signal. Meanwhile, the effect is expected to be further improved through combined strategies such as gene modification on the mesenchymal stem cells to interfere the activity of conditional antigen presenting cells, nanocrystallization on traditional Chinese medicine active monomers and the like. The invention provides application potential in prevention and treatment of various diseases, including acute pancreatitis, multiple sclerosis, arthritis, lupus, sepsis, hepatitis, Parkinson's disease, colitis, graft versus host disease, chronic infection and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to novel methods for promoting the immunosuppressive activity of mesenchymal stem cells (MSCs). Background Art

[0002] Mesenchymal stem cells are a type of adult stem cells that originate from the mesoderm. They have the potential for self-renewal and multidirectional differentiation and can differentiate into a variety of interstitial tissues, such as bone marrow, cartilage, fat, bone marrow hematopoietic tissue, etc. Clinically, they are widely used to treat a variety of diseases including cardiovascular diseases, orthopedic diseases, nervous system diseases, dermatology, rheumatism and immunology, inflammatory diseases, immune rejection diseases, obstetrics and gynecology, respiratory diseases, ophthalmology and stomatology, etc. Their rich sources include bone marrow, umbilical cord blood, umbilical cord tissue, placental tissue and adipose tissue, which facilitates their clinical application.

[0003] So far, there are more than ten new stem cell drugs on the market abroad. In my country, more than ten mesenchymal stem cell new drugs have applied for clinical approval. The development of stem cell drugs has also become one of the goals of key projects. With the promulgation of the Technical Guidelines for Research and Evaluation of Cell Therapy Products and the Technical Guidelines for Clinical Trials of Stem Cell Products, the standards for stem cell therapy as a drug application have been clarified, providing more targeted suggestions for drug development and registration applicants and researchers conducting drug clinical trials, which undoubtedly greatly promotes the development of stem cell clinical transformation and application. At present, there are more than 100 registered stem cell clinical research institutions in my country, and more than 70 registered stem cell-related research projects. Studies have shown that MSCs also have an intervention effect on acute pancreatitis. It can regulate severe acute pancreatitis through multiple effects, including: (1) Reducing inflammation of pancreatic tissue. MSCs can downregulate pro-inflammatory markers in animals with severe pancreatitis, including IL-1β, IL-6, and TNF-a, while increasing anti-inflammatory cytokines such as IL-10; (2) Immunomodulation. MSCs can reduce the percentage of CD3+T cells in pancreatic tissue and increase the percentage of FoxP+ regulatory T cells; (3) Angiogenesis. MSCs pretreated with stromal cell-derived factor 1α (SDF-1α) can promote the increased expression of vascular markers (CD31 and vWF) in pancreatic tissue, that is, promote angiogenesis in pancreatic tissue; (3) Reduce acinar cell apoptosis. MSCs may reduce acinar cell damage by alleviating oxidative stress; (4) Antioxidation. MSCs increase the antioxidant activity of local pancreatic tissue, such as superoxide dismutase (SOD), glutathione peroxide (GPX) and HO-1, and reduce the level of malondialdehyde (MDA), which is a product of lipid peroxidation during acute pancreatitis.

[0004] Although MSCs have shown promise in the intervention of acute pancreatitis and there are many benefits to the clinical transformation of stem cells, there are still no reports of clinical studies on the use of MSCs in acute pancreatitis. The main reason is that the intervention effect of MSCs on severe acute pancreatitis has not yet reached the requirements of clinical treatment, and the efficacy needs to be improved. It is well known that MSCs do not have an immunomodulatory effect without stimulation. Only under the stimulation of inflammatory factors, MSCs regulate inflammation through mechanisms such as inflammatory regulatory signal axes, inflammatory inhibitory molecules, growth factors, exosomes, chemokines, complement components or multiple metabolites. Many researchers have tried to regulate the anti-inflammatory, anti-tumor and regenerative effects of MSCs by regulating MSC immunomodulatory-related molecules. Common stimulation and regulation methods include: (1) hypoxia-induced MSCs increase the secretion of growth factors and anti-inflammatory molecules; (2) pro-inflammatory regulation induces MSCs to secrete anti-inflammatory molecules; (3) promote MSC size increase to promote the secretion of anti-tumor and anti-inflammatory molecules. The present invention aims to promote the intervention effect of MSC on severe pancreatitis by regulating its anti-inflammatory effect, and to provide new ideas and methods for the clinical treatment of severe pancreatitis.

[0005] It has been reported in the literature that hMSC pre-stimulated with IFN-γ has a stronger immunomodulatory effect, mainly because IFN-γ can upregulate a variety of immune active factors such as IDO, PD-L1, PGE2, CCL8, CXCL9 and CXCL10 through the interferon signaling pathway. The applicant's previous work found that the chemokine-iNOS / IDO axis plays an important role in MSCs regulating acute pancreatitis. MSCs reduce the recruitment of macrophages, neutrophils and CD4+T cells in the pancreatic infiltrating lymphocytes at the lesion site during the progression of the disease through this pathway. Some researchers have constructed an injectable synthetic hydrogel coupled with IFN-γ to encapsulate hMSC for the treatment of mouse colon mucosal wounds, suggesting that it has a good repair effect. It has also been reported that the therapeutic effect of MSC pretreated with IFN-γ on colitis can be further improved. In addition, some clinically used drugs such as tamoxifen and chloroquine phosphate can be combined with IFN-γ to further promote MSC to secrete the above-mentioned immunomodulatory active factors and enhance the immunomodulatory effect of MSC by regulating the classical or non-classical interferon signaling pathway. In view of the inhibitory effect of some drugs on MSC proliferation, some active monomers of traditional Chinese medicine were screened to provide a variety of options for MSC immunomodulatory molecules.

[0006] Although allogeneic human umbilical cord mesenchymal stem cells are a convenient cell source for stem cell therapy, immune rejection is the main obstacle to the clinical application of allogeneic stem cells. For mesenchymal stem cells that have not been pretreated, human leukocyte antigen class I molecules (HLA-I) are the main molecules of rejection. MSCs pretreated with IFN-γ are mainly rejected by HLA-II molecules. Many researchers have used gene editing technologies such as CRISPR / Cas9 to interfere with HLA light chain proteins (β2-microglobulin) to avoid immune rejection and improve the transplant survival rate of stem cells. This suggests that gene editing technology for MSCs plays a role in improving their effects.

[0007] Drug carriers such as nanoparticles or liposomes have the combined effects of accelerating the rate of drug cellular endocytosis, increasing the amount of drug endocytosis, prolonging the intracellular retention time of drugs, and reducing drug toxicity. Nanoparticles can fully exert the above effects when used in vitro, and can avoid the defects of being easily cleared by the endothelial reticular system when used in vivo, having a short plasma half-life, and low concentration at the target site.

[0008] Based on the above research results, the applicant proposed a new method for pre-treating MSCs in vitro with interferon pathway-regulating drug nanoparticles / liposomes and using them for severe acute pancreatic intervention. The regulatory effect of drugs or compounds on interferon signals is used to enhance the immunomodulatory effect of MSCs. The preparation of drug-loaded nanoparticles or liposomes further promotes the regulatory effect of drugs or compounds on MSCs, reduces side effects, and minimizes the risk of in vivo application of nanocarriers. It provides new ideas and methods for the treatment of various inflammatory diseases in clinical practice. Summary of the invention

[0009] The present invention describes novel methods for modulating the immunosuppressive effects of MSCs or genetically modified MSCs.

[0010] In practice, immunosuppression is enhanced in a subject (compared to a subject not receiving such treatment) by administering an effective amount of a composition comprising isolated MSCs that have been treated with IFNγ and a Chinese herbal active monomer.

[0011] Preferred methods and materials are described below in the form of examples, which are intended to illustrate but not limit the present invention. Those skilled in the art will recognize that the methods and materials described here are similar or equivalent and can be used to practice or detect the methods and materials of the present invention. Other features and advantages of the present invention will be apparent from the detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 is the primer sequence.

[0013] Figure 2 The mRNA expression of various molecules in UMSCs stimulated by AE. A: AE (10ug / ml) combined with IFN-γ 5ng / ml pretreatment of UMSCs for 24 hours, and changes in multiple molecular levels. B (1): AE stimulation of UMSCs time point screening; B (2): AE stimulation of UMSCs concentration screening. C: IDO protein expression in UMSCs pretreated with AE (20ug / ml) combined with IFN-γ 5ng / ml for 36 hours. NT: untreated group; I-AE: IFN-γ combined with AE group; AE: 10 ug / ml, AE+: 20 ug / ml, AE++: 30 ug / ml, AE+++: 40ug / ml combined with IFN-γ 5ng / ml stimulated UMSCs for 24 hours. (n=3) *p<0.05, **p<0.01, ***p<0.001.

[0014] Figure 3 The effect of different drug concentrations on cell proliferation. UMCs were pretreated with different drug concentrations for 24 hours.

[0015] Figure 4 The expression of PD-L1 in UMSCs stimulated by different concentrations of AE. A: Flow cytometry staining; B: Statistical graph of flow cytometry results; C: PD-L1 protein expression in different groups of UMSCs. NT: Untreated group; IFN: IFN-γ (5ng / ml) pretreated UMSCs for 24h; I-AE: IFN-γ combined with AE group; AE: 10 ug / ml, AE+: 20 ug / ml, AE++: 30 ug / ml, AE+++: 40ug / ml combined with IFN-γ 5ng / ml stimulated UMSCs for 24 hours.

[0016] Figure 5 It is the purity analysis of CD4+T cells. It is the purity determination of spleen cells CD4+T cells and the purity identification of CD4+T cells after sorting.

[0017] Figure 6 It is a CD4+T cell activation assay. NT: CD4+T cells without CD3 / 28 activation; CD3 / 28: CD4+T cells activated with CD3 / 28; UMCs: co-cultured with untreated UMCs; IFN: co-cultured with UMCs pretreated with IFN-γ for 24 hours; I-AE: co-cultured with UMCs pretreated with AE combined with IFN-γ for 24 hours.

[0018] Figure 7The expression of IDO P-ERK in UMSCs after different treatments. A: NT: UMSCs without any pretreatment; IFN: UMSCs pretreated with IFN-γ 5ng / ml for 24h; IFN-AE+: UMSCs pretreated with AE 20ug / ml combined with IFN-γ 5ng / ml for 24h. B: NT, IFN and IFN-AE+ are the same as in Figure A. I-PD: UMSCs were pretreated with PD98059 for 24h and then with IFN-γ for 24h.

[0019] Figure 8 The expression of IDO P-stat1 in UMSCs after different treatments. NT: UMSCs without any pretreatment; IFN: UMSCs pretreated with IFN-γ 5ng / ml for 24h; I-AE+: UMSCs pretreated with AE 20ug / ml combined with IFN-γ 5ng / ml for 24h.

[0020] Fig. 9 It is the pancreatic tissue pathology scoring standard.

[0021] Fig.10 It is the lung tissue pathology scoring standard.

[0022] Fig.11 The following are the changes of pancreatic inflammation indexes after modeling. A: Serum amylase determination of mice; B: HE staining and pathological scoring of pancreas. NT: healthy control group, SAP: severe acute pancreatitis model group.

[0023] Fig.12 This is the immunofluorescence staining of CD4+T cells in pancreatic tissue. NT: healthy control group; SAP: severe acute pancreatitis modeling group.

[0024] Fig.13 are the mRNA levels of IDO and CIITA in different groups of UMSCs.

[0025] Fig.14 is the mRNA level of silencing CIITA gene. NT: control group UMCs; si-NC: UMCs transfected with negative control plasmid; si-CIITA: UMCs transfected with si-CIITA.

[0026] Fig.15The changes of pancreatic inflammation indexes after UMSCs treatment in different groups. A: Serum amylase determination of mice; B: HE staining and pathological scoring of pancreas. NT: healthy control group; SAP: untreated UMSCs group; IFN: UMSCs pretreated with IFN-γ; I-AE: UMSCs pretreated with AE combined with IFN-γ (n=3, 3 mice in each group). *p<0.05, **p<0.01, ***p<0.001.

[0027] Fig.16 Figure 3 HE staining and pathological scores of lungs after UMSCs treatment in different groups.

[0028] Fig.17 is TNF-α determination. A: standard curve of ELISA detection of TNF-α; B: TNF-α determination of lung lavage fluid, NT: healthy control group; SAP: untreated UMCs group; IFN: UMCs treatment group pretreated with IFN-γ; I-AE: UMCs treatment group pretreated with AE combined with IFN-γ (n=3, 3 mice in each group).

[0029] Fig.18 is immunofluorescence staining of CD4+T cells in pancreatic tissue. NT: healthy control group; SAP: untreated UMCs group; IFN: UMCs treated with IFN-γ pretreatment; I-AE: UMCs treated with AE combined with IFN-γ pretreatment (n=3, 3 samples in each group). DETAILED DESCRIPTION

[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs, and will be understood to have the meanings described below. All publications and patents mentioned herein are hereby fully introduced by way of reference. In the event of a conflict, the present specification including definitions will apply. In addition, materials, methods and embodiments are illustrative only and are not intended to be limiting.

[0031] The term "effective amount" as used herein refers to an amount of stem cells, active monomers of traditional Chinese medicine, or a therapeutic composition containing both that is sufficient to modulate, weaken, or induce an immune response (i.e., inhibition of T cell response) in a subject, thereby alleviating at least one sign or symptom of the disease or disorder being treated.

[0032] As used herein, the terms "treat", "treat" or similar terms refer to the alleviation of disease signs or symptoms by administering a composition to a patient in need of such treatment. "Treatment" does not require complete alleviation of disease signs or symptoms or cure. At the cellular level, the term may include differences in signal pathway activation, survival ratio, etc. in cells treated with the agent compared to untreated cells or controls used.

[0033] The terms "administration" or "treatment regimen" as used herein include single treatment delivery or multiple or repeated delivery, or controlled delivery treatment of any of the individual components of the present invention or a combination thereof. These terms are further intended to include delivery methods such as local delivery, systemic delivery, intravascular delivery, intramuscular delivery, intraperitoneal delivery, delivery within the brain blood barrier, organ-specific intravenous injection delivery, or delivery via other different routes.

[0034] An embodiment of the present invention confirms that the immunosuppression of MSC needs to be triggered by inflammatory cytokines, especially IFNγ. In the absence of inflammatory cytokines, MSC does not obtain their immunosuppressive properties, and the combined use of active monomers of traditional Chinese medicine that promote the signal pathway activated by IFNγ will significantly amplify the immunosuppressive properties of MSC alone combined with IFNγ. The present invention describes the addition of IFNγ and active monomers of traditional Chinese medicine, mainly active monomers of rhubarb anthraquinones, to achieve a strong and lasting inhibitory function of MSC. This effect is particularly capable of inhibiting the proliferation / activation of T cells under inflammatory conditions, or the activation of other inflammatory cells including macrophages. At the same time, with the help of nanotechnology, the activation effect is promoted by increasing the uptake of small molecules. Active monomers such as rhubarb and aloe-rhubarb rhubarb have anti-inflammatory effects themselves, and to a certain extent, they will also play a synergistic therapeutic role.

[0035] Another embodiment of the present invention also suggests that although some active monomers can significantly upregulate MSC-related immunosuppressive molecules, they also upregulate human leukocyte antigen (HLA) family molecules, which are important antigenic substances that mediate MSC transplantation immune rejection reactions, resulting in accelerated clearance of MSC after reinfusion. In response to this problem, the present invention proposes to prevent the influence of this process by means of gene silencing, and the results significantly improve the in vivo effect of MSC.

[0036] The following non-limiting examples are provided to further illustrate the present invention. Example Example 1

[0037] Reagents: DMEM low-glucose medium (Shanghai Yuanpei Biotechnology Co., Ltd.), penicillin-streptomycin (Dalian Meilun Biotechnology Co., Ltd.), stem cell culture serum Elite Gro (Dakoway Biotechnology Co., Ltd.), dimethyl sulfoxide, tetramethylthiazolyl blue (MTT) (Sigma-Aldrich), rhamnosin, aloe-rhamnosin (Chengdu Desite Biotechnology Co., Ltd.), IFN-γ (Beijing BIOLEGEND Biotechnology Co., Ltd.), chloroform (Chengdu Kelong Chemical Co., Ltd.), reverse transcription kit, Trizol and SYBR green (Beijing Qingke Biotechnology Co., Ltd.), tris (hydroxymethylaminomethane) (Tris), sodium dodecyl sulfate (SDS) and glycine (Shanghai Yuanye Biotechnology Co., Ltd.), RIPA lysis buffer (Shanghai Biyuntian Biotechnology Research Institute), cocktail Protease inhibitors and phosphatase inhibitors (Selleck Biotechnology Co., Ltd., USA), protein pre-stained marker (Hunan Aikerui Biotechnology Co., Ltd.), NC membrane (Beijing North Tongzheng Biotechnology Co., Ltd.), ammonium persulfate (AP) and TEMED (Wuhan Boster Biotechnology Co., Ltd.), poly(lactic-co-glycolic acid) (PLGA, 50:50) (Shandong Institute of Medical Devices (China)), polyvinyl alcohol (PVA) (Sigma-Aldrich Company), chloroform and methanol (Tianjin Komiou Chemical Reagent Co., Ltd.).

[0038] Extraction and culture of UMSCs. The main methods for extracting umbilical cord mesenchymal stem cells (UMSCs) are enzyme digestion and explantation. This experiment mainly adopts the explantation method, which is easy to operate and has a high success rate of cell culture. Umbilical cord tissue was obtained from healthy pregnant women, and the experimental plan has been approved by the Ethics Committee of Sichuan University. The steps are as follows: (1) Under a sterile environment, take a 5-6 cm long tissue from the junction of the umbilical cord and the placenta, soak it in sterile PBS containing 1% double antibody, and transport it back to the laboratory on ice. (2) Take out the umbilical cord tissue in the clean bench, rinse it repeatedly with PBS containing double antibody, transfer it to a clean tray, and add sterile PBS to immerse the tissue. (3) Use forceps to clamp one end of the umbilical cord, and three blood vessels can be seen: the thicker one in the middle is the umbilical vein, and the thinner ones at both ends are the umbilical arteries. (4) Use ophthalmic scissors to cut along the umbilical vein, remove the blood vessels, and wash the blood stains in the culture medium. (5) Hold the ophthalmic forceps with both hands, clamp and fix with one hand, and tear along the outer wall of the umbilical artery in the direction of the umbilical cord twist with the other hand. Do this for both blood vessels. If a strong and complete umbilical artery is visible, remove it. (6) Then inoculate 20-25 tissue blocks in a 100 cm2 culture dish, place it in an incubator, and let it stand for 2 hours at 37°C and 5% carbon dioxide. Then add 2 ml of culture medium, and add 10 ml of culture medium again after 24 hours. Do not shake the culture dish within 2-3 days to allow the tissue blocks to adhere. (7) After 3 days, change the medium halfway, and then change the medium once every 5 days. After 12 days of culture, change the medium to remove most of the floating tissue. When ≥80% of the cells are attached to the wall or (then) more local cell colonies are dense, you can start subculturing. Note: 7-10 days after the initial cell growth of the explant, the cell growth reaches 70% fusion. Note that non-adherent tissue pieces will not induce any cell growth unless they adhere to the plastic. Care must be taken not to disturb the culture dish so that adherent tissue pieces do not fall off. If there are any floating pieces after the first three days of culture, they can be salvaged by transferring them to a new flask to allow them to attach.

[0039] Steps for cell passaging, freezing and thawing. When the cells grow to 90%, remove the culture medium, add 2ml of trypsin, discard the excess trypsin after uniform activity and place in an incubator for digestion for 1-2 minutes. Use complete culture medium to blow the digested cells into a single cell suspension, centrifuge and wash, and pass them at a ratio of 1:3. Take the third-generation cells and collect them after digestion, and stain them with CD73, CD105, and CD34 flow antibodies for identification. Cell freezing: When there are more cells to be extracted, digest them according to the above steps, mix the single cell suspension with dimethyl sulfoxide (DMSO) at a ratio of 9:1 and add them to a 1.5m cryopreservation tube. After marking, transfer them to a cryopreservation box and place them in a -80℃ refrigerator overnight, and then transfer them to liquid nitrogen for long-term storage for subsequent experiments. Cell thawing: When UMSCs are continued to be cultured after freezing, cell thawing needs to be performed first. Cell thawing is very critical. Careless operation can easily cause cells to be damaged and die during thawing, affecting the subsequent use of cells.

[0040] The main steps include: (1) Take the frozen cells out of liquid nitrogen and quickly shake them in a 37°C water bath to promote their thawing (the cells should be thawed as quickly as possible; too long a time will affect the cell viability and result in too many dead cells); (2) Add 1 ml of preheated DMEM complete medium, blow gently to mix, and transfer to a 15 ml centrifuge tube; (3) Centrifuge at 1200 rpm for 3 min and discard the supernatant; (4) Add 10 ml of DMEM medium to wash, centrifuge at 1200 rpm for 3 min and discard the supernatant; (5) Add 1 ml of DMEM complete medium, blow gently, inoculate in a 10 cm culture dish containing 9 ml of complete medium, and culture in a cell culture incubator containing 5% CO2.

[0041] Aloe-emodin (AE) was used to pretreat UMSCs. AE was prepared as a 10 mg / ml stock solution using DMSO and stored at -20°C. When used, it was completely dissolved and mixed, and diluted with culture medium to the required concentration according to the following procedures: (1) 3×10^5 cells of UMSCs were seeded into a 6-well plate and incubated overnight. (2) The culture medium was discarded and replaced with 2 ml of fresh complete culture medium containing IFN-γ 5 ng / ml and different AE concentrations. The AE concentrations were 10 ug / ml, 20 ug / ml, 30 ug / ml, and 40 mg / ml, respectively. Cells without any treatment were used as the control group. (3) Mix well and incubate in a static incubator. (4) After 24 hours, total cell RNA was extracted to determine the mRNA levels of related molecules. (5) After 36 hours, total cell protein was extracted and the IDO protein content was determined by WB experiment.

[0042] Total RNA extraction from cells. This experiment was conducted in a 12-well plate. The cell culture medium was discarded, the cells were washed twice with PBS, and then 1 ml of Trizol reagent was added to the well plate. The cells were lysed at room temperature for 3 minutes and then transferred to a 1.5 ml sterile enzyme-free centrifuge tube. The operation steps are as follows: (1) Trizol lysed the cells for 3 minutes. (2) 200 ul of chloroform was added, the cells were shaken vigorously for 20 seconds, and then allowed to stand for 5 minutes. (4) Centrifuged at 4°C, 12000 g, for 10 minutes. (5) 400 ul of the transparent aqueous phase containing RNA was carefully pipetted into a new centrifuge tube, 500 ul of isopropanol was added, and the tube was inverted to mix. (6) The tube was incubated at room temperature for 10 minutes to precipitate the RNA. (7) Centrifuged at 4°C, 12000 g, for 10 minutes. (8) After centrifugation, a white RNA precipitate was visible. The supernatant was discarded, 1 ml of 75% ethanol was added, and the tube was inverted to mix and the precipitate was washed. (9) Centrifuge, 4°C, 12000g, 10 min. (10) Discard the supernatant, open the lid, and air-dry the RNA until it becomes transparent. (11) Add an appropriate amount of DEPC water to dissolve the RNA, and measure the RNA concentration and A260 / 230, A280 / 260 using a Nanodrop instrument.

[0043] RT-QPCR. The extracted total RNA was first reverse transcribed into cDNA, and then semi-quantified by real-time fluorescence quantification. This study used the Takara reverse transcription kit. According to the manufacturer's instructions, 1ug ​​of total RNA, 0.5ul of 5× Prime Script Buffer, 2ul of Prime Script RT Enzyme Mix, 0.5ul of Oligo dT Primer (50uM), 0.5ul of Random 6 Primer (100uM) were added, and finally RNase Free d2H2O was added to the 10ul system. Reverse transcription was performed according to the preset program, 37℃ 15min, 82℃ 5s and 4℃ 10min. Then, according to the fluorescence quantitative PCR kit, the sample was prepared, 2×TSINGKE® Master qPCR Mix (SYBR Green I with UDG) 5ul, 10 µM upstream primer 0.4ul, 10 µM downstream primer 0.4ul, template DNA 2ul, ddH2O 2ul; the sample was placed on the fluorescence quantitative PCR instrument and reacted according to the preset program, UDG incubation, 50℃, 2min 1cycle; pre-denaturation, 95℃, 2min, 1cycle, 95℃, 15s, 40 cycles; cycle reaction, 60℃, 30s, and fluorescence signal collection at 60℃.

[0044] Western Blot experiment Total protein extraction from cells: (This experiment was performed in a 6-well plate according to the following steps) a. Prepare protein lysis buffer: RIPA lysis buffer mixed with protease inhibitor at a ratio of 100:1, and place on ice for later use. b. Discard the cell culture medium, wash twice with 4℃ pre-cooled PBS, and discard. c. Add 80ul of protein lysis buffer and scrape the cells on ice with a cell scraper. d. Transfer the cells to a 1.5ml centrifuge tube and lyse on ice for 15min. e. Centrifuge at 4℃, 12000rpm, 10min. f. Carefully aspirate the supernatant into another clean 1.5ml centrifuge tube. g. Determine the protein concentration by BCA method. h. Mix the protein with 5× protein loading buffer, denature the protein in a 100℃ metal bath for 10min, cool to room temperature and store at -20℃.

[0045] SDS-PAGE gel electrophoresis: Loading: Place the prepared gel in the electrophoresis tank, add electrophoresis solution, and slowly inject the protein marker and sample into the sample well with a 10ul pipette, and mark it. Electrophoresis: Turn on the power, adjust the button to set the voltage to 120V, the time is 1.5h, and the voltage is constant. Observe the sample tank every 30 minutes, and stop the electrophoresis after separating your target protein according to the position of the marker. Transfer: Prepare 10× transfer solution and dilute it to 1× with pure water when using. b. Carefully take out the gel in the electrophoresis tank and place it in the transfer solution (do not let it dry). c. Take out the cut PVDF membrane, prepare the transfer device, and place the black bottom plate - 1 layer of sponge - 3 layers of filter paper - membrane - gel - 3 layers of filter paper - 1 layer of sponge. After completion, place it in the transfer tank to start transfer. d. Place the device in an ice bath, turn on the power and start transfer. Constant voltage 300 mA; transfer time 1.5h, adjust the transfer time according to the molecular weight of the target protein. Be careful not to insert the electrode incorrectly; e. After the transfer, take out the PVDF membrane and place it in TBS buffer. Note that the PVDF membrane should be kept moist at all times. Immunohistochemical hybridization and color development: a. Prepare 1×TBS and add 0.02% Tween-20, namely TBS / T: b. Wash the membrane 3 times with 1×TBS / T, 10 minutes each time, on a shaker. c. Place the PVDF membrane in the blocking buffer, shake slowly on a shaker at room temperature, and block for 1 hour. c. Wash the membrane 3 times with 1×TBS / T, 10 minutes each time, on a shaker. e. Place the PVDF membrane in the hybridization box, add the primary antibody of appropriate concentration, shake slowly on a shaker at 4 ℃, and incubate overnight. f. The next day, take out the membrane coupled with the primary antibody, 1×TBS / T, 3 ×10 minutes, on a shaker. g. Place the membrane in the antibody incubation box with the secondary antibody, incubate at 37 ℃ for 1 hour, on a shaker at room temperature. h. Wash the membrane 3 times with 1× TBS / T, 5 min each time, on a shaker. I. Development: Perform development according to the luminescence method. Mix color development solution A and B in a 1:1 ratio, put the membrane into the machine, add ECL solution drops to the membrane, take pictures immediately, and adjust the band position and exposure, and finally use software for semi-quantitative analysis (using actin as an internal reference).

[0046] MTT assay. The toxicity of AE on the proliferation of UMSCs was determined by MTT assay. UMSCs were added to 96-well plates at 2×10^3 cells per well, and the cells were allowed to adhere to the wall overnight. The cells were treated with free drugs at different final concentrations (10ug / ml, 20ug / ml, 30 ug / ml, 40ug / ml, 60 ug / ml, 80 ug / ml, 100 ug / ml) for 24 hours. The culture medium was then discarded (given that the drug itself has color) and 20ul of MTT complete culture medium (5mg / mL) was added to incubate the cells for 6 hours. The culture medium was discarded, 150μl of DMSO was added to each sample well, and the well was placed on a shaker for 10 minutes (to allow DMSO to completely dissolve the crystals formed in the well plate), and the well was detected by the machine at a wavelength of 570nm. The readings of untreated cells were used as a control to calculate cell viability. Example 2

[0047] AE pretreatment upregulates IDO / PD-L1 in UMSCs. First, we used AE (10ug / ml) combined with IFN-γ (5ng / ml) to pretreat UMSCs in vitro for 24 h, and measured the changes in the levels of molecules that are generally recognized to play an immunosuppressive role in the mRNA of UMSCs after different treatments (primers are shown in Table 2.13). Figure 2 As shown in A, when the concentration of AE is 10ug / ml, IDO and PD-L1 molecules can be significantly upregulated. Considering the effects of treatment time and drug treatment concentration, we then screened the drug treatment time point and drug treatment concentration. First, we selected three time points of 1h, 12h and 24h for sampling, and found that IDO and PD-L1 at the 24h time point increased more significantly than the other two time points ( Figure 2 B(1)); Then four drug concentrations of 10ug / ml, 20ug / ml, 30ug / ml and 40ug / ml were selected for pretreatment for 24h and samples were collected. Figure 2 As shown in B(2), when the AE concentration was 20ug / ml, the levels of IDO and PD-L1 increased most significantly. The treatment with higher concentrations of the drug did not further increase the levels of the two drugs, indicating that the drug concentration had reached saturation. Microscopic observation also showed that when the drug concentration was greater than or equal to 30ug / ml, a large amount of free drug was precipitated in the culture medium. In summary, the stimulation effect was best when AE was 20ug / ml. At the same time, the IDO protein was determined by immunoblotting ( Figure 2 C), consistent with the qPCR results, AE combined with IFN significantly increased IDO expression.

[0048] The toxic effects of AE on UMSCs. Figure 3As shown in the figure, the results of the cytotoxicity test showed that AE had a certain toxicity to UMSCs, and as the drug concentration increased, the drug's inhibitory effect on cell proliferation increased, but the change was not significant and finally tended to be around 70%. The concentration of 20ug / ml we selected had little effect on cell proliferation, and the cell proliferation rate reached about 80%.

[0049] MSCs mainly act by their paracrine mechanism, and their pharmacological effects can be achieved through gene editing or pretreatment. Pretreatment of mesenchymal stem cells with hypoxia, oxidative stress, heat shock, starvation, endogenous small molecules or inflammatory cytokines has been shown to improve their survival rate and efficacy. There is no literature reporting the combination of traditional Chinese medicine active monomers with IFN-γ to improve the effect of MSCs and regulate their immunosuppressive effects. By measuring mRNA and protein levels in vitro, we found that AE combined with IFN-γ pretreatment can significantly upregulate IDO and PD-L1 in UMSCs. Molecules that exert immunosuppressive effects in MSCs include PGE2, TSG-6, IDO, iNOS, TGF-β, HO-1, PD-L1, etc. Through in vitro experiments, we found for the first time that AE can significantly enhance the levels of IDO and PD-L1 in UMSCs. However, the exact signaling mechanism involved is still unclear and needs further verification. Through the MTT experiment, it is known that AE has a certain inhibitory effect on the proliferation of UMSCs and has a certain toxicity.

[0050] In antigen presenting cells (APCs), the expression of indoleamine 2,3-dioxygenase (IDO), induced by interferon-γ (IFN-γ) and other proinflammatory cytokines, catalyzes the conversion of tryptophan to kynurenine and has been identified as a major immunosuppressive effector pathway that inhibits T cell responses to self-antigens and fetal alloantigens in vivo [123,124]. IDO has been identified as a switch for human MSCs to exert their immunosuppressive effects

[125] . Programmed death ligand-1 (PD-L1) is a member of the B7 family of structurally related cell surface proteins that regulate T cell activation (TCA) and tolerance through the T cell receptor (TCR). It is constitutively expressed on dendritic cells, monocytes after IFN-γ and lipopolysaccharide treatment, and keratinocytes after IFN-γ treatment, and is also expressed on activated CD3+ cells. When PD-L1 binds to its receptor PD-1, the tyrosine in the ITSM (tyrosine-based switch motif) region is phosphorylated, and the protein tyrosine phosphatase molecules are recruited to dephosphorylate the downstream effector molecules. It can transduce negative signals and thus negatively regulate immune function, playing an important role in autoimmune diseases, transplant rejection and other reactions; the PD-L1 / PD-1 pathway has become a research hotspot for autoimmune diseases. It has been reported that this pathway may also be important in contact-dependent immune regulation of MSCs. Example 3

[0051] Reagents: IL-2, PE-anti-CD4, FITC-anti-CD69, anti-CD28, anti-CD3 and anti-PD-L1 (Beijing BIOLEGEND Biotechnology Co., Ltd.), 1640 medium (Shanghai Yuanpei Biotechnology Co., Ltd. (China)).

[0052] Experimental cells. C57 mice used to extract mouse spleen cells were purchased from the Experimental Animal Center of Sichuan University. All animal experiments in this project were approved by the Ethics Committee of Sichuan University and were conducted in strict compliance with animal ethics.

[0053] Isolation and purification of CD4+T cells. (1) Kill mice by cervical dislocation and soak them in anhydrous ethanol for 40 minutes; (2) Isolate the spleen under sterile conditions; (3) Remove the mouse spleen and place it in a culture dish containing 10ml of 1640 culture medium containing 2% FBS, and remove the connective tissue or fat on the spleen tissue; (4) Place the spleen tissue in a 70um cell sieve, and under the sieve is a 50ml centrifuge tube containing a small amount of culture medium; (5) Use the flat end of the syringe to grind the spleen in a gentle and circular manner (add culture medium to rinse the sieve while grinding), until the spleen tissue turns white and the culture medium becomes clear, then rinse the sieve again with 3ml of culture medium; (6) Centrifuge at 1500rpm for 5min, collect the cells, and discard the supernatant ; (7) Add 1 ml of red blood cell lysis buffer and let stand at room temperature for 8 minutes; (8) Add 10 ml of culture medium, centrifuge at 1500 rpm for 5 minutes, remove the supernatant, and resuspend with appropriate complete culture medium to obtain spleen single cell suspension; (9) Add appropriate amount of PE-CD4 antibody for staining, as shown in the method, (10) Flow cytometry is used to detect the proportion of CD4+T cells in spleen single cells (normal range 15%-18%) to ensure that all CD4+T cells in spleen single cells are stained; (11) Use a flow cytometer to sort sterile CD4+T cells; (12) Centrifuge at 1500 rpm for 5 minutes to collect CD4+T cells, and then measure the purity of the sorted CD4+T cells by flow cytometry.

[0054] Co-culture of CD4+T cells and UMSCs. (1) Plate coating: Dilute CD3 and CD28 antibodies with commercial PBS (antibiotic-free, used in a clean bench), and incubate at 4 degrees overnight at 2 micrograms of CD3 and CD28 antibodies per well of a 24-well plate. (2) Co-culture: Wash the coated well plate twice with PBS, inoculate UMSCs that have undergone different treatments in advance into a 24-well plate (to allow the UMSCs to adhere to the bottom of the well plate), and inoculate 0.6-1X10^6 CD4+T cells sorted by a flow cytometer into each well of a 24-well plate. The ratio of UMSCs to CD4+T cells is 1:4. The full culture medium is 1640+20% FBS+double antibody+IL-2 50ng / ml+2-ME 50uM. Continue to culture for 2-3 days (the culture medium should not turn yellow). Whether the culture medium turns yellow determines whether to perform a half-medium change. (3) Cell proliferation assay: For cells to be assayed for proliferation, disperse them in PBS containing CFSE (1 μM). The CFSE stock solution can be prepared into a 5 mM DMSO solution and stored at -20°C. After staining on ice for 1 minute, wash the cells three times with full culture medium and continue to culture according to the method in 2 above. (4) CD4+ T cell activation assay: After 72 hours of culture, detect CD69 on the surface of CD4+ T cells.

[0055] Flow cytometry experiment. Adjust the obtained cell concentration to 10^6 cells / 100ul and dispense into 1.5ml ep tubes. First, add anti-CD16 / CD32 antibody and incubate on ice for 10min to prevent non-specific antibody binding. Number the ep tubes and add the required antibodies for staining, incubate on ice for 30min, mix every 10min (staining is sufficient), add 1ml PBS to wash after staining, centrifuge at 2500rpm, 5min, 4℃, discard the supernatant and add 0.5ml PBS. If you need to measure overnight, you can fix it, wash it with PBS, discard the supernatant, add 0.5ml 4% paraformaldehyde and fix it at room temperature in the dark for 15min, add 1ml PBS after fixation, centrifuge at 3500rpm, 5min, 4℃, discard the supernatant, add 0.5ml PBS and resuspend it at 4℃ for storage. Detection was performed using BD-Fortessa flow cytometer. Data were analyzed using Flowjo software. Example 4

[0056] Changes in PD-L1 expression in UMSCs after AE pretreatment. According to the literature, PD-L1 is not expressed in UMSCs lysates, but PD-L1 is expressed on the surface of UMSCs. This study confirmed the expression of PD-L1 on the surface of UMSCs by flow cytometry ( Figure 4 A), Western blotting confirmed that PD-L1 was not expressed in the protein lysate ( Figure 4 C). This indicates that UMCs mainly exert immunosuppressive effects by releasing PD-L1 through EVs.

[0057] Purity identification of CD4+T cells. Single cell suspension was extracted from mouse spleen, and then CD4+T cell staining was performed for subsequent CD4+T cell flow cytometry sorting. The proportion of CD4+T cells contained in a mouse spleen cell is about 15%, such as Figure 5 As shown, it means that all CD4+T cells in the extracted spleen cells have been stained. The purity of CD4+T cells after our sorting is about 96%, which is in line with expectations.

[0058] CD4+T cell activation assay. The CD4+T cells sorted above were inoculated into the well plates of different treatment groups at a ratio of 1:4 (UMSCs:CD4+T cells). CD4+T cells without CD3 / 28 pre-coating were used as negative controls, CD4+T cells pre-coated with CD3 / 28 were used as positive controls, and the remaining groups were co-culture groups, in which the UMSCs were pre-treated differently. Figure 6 It can be seen that CD4+T cells were effectively activated in the wells pre-coated with CD3 / 28, and the proportion of CD4+CD69+T cells after activation was about 33%. The activation of CD4+T cells in the UMSCs co-culture group was effectively inhibited, and the CD4+T cell activation rate of the UMSCs group without pretreatment decreased significantly. The activation inhibition rate of the UMSCs group pretreated with IFN-γ and AE combined with IFN-γ for 24h was significantly lower than that of the UMSCs group without pretreatment. The inhibition rate of the UMSCs group pretreated with AE combined with IFN-γ was better than that of the UMSCs group pretreated with IFN-γ alone, but the activation inhibition rate between the two groups was not significant.

[0059] Western blotting and flow cytometry verified that the UMSCs lysate supernatant did not express PD-L1, which was consistent with the literature reports. PD-L1 was expressed on its surface, and the flow cytometry results were consistent with the QPCR results. By successfully isolating and purifying CD4+T cells and co-culturing them with UMSCs, it was found that untreated UMSCs had a certain inhibitory effect on the activation of CD4+T cells, which may be explained by the fact that the flow cytometry results of untreated UMSCs showed a certain expression of PD-L1. Untreated UMSCs did not express IDO, and IDO was induced expression rather than constitutive expression. The activation effect of pretreated UMSCs on CD4+T cells was further enhanced, and the inhibition rate of aloe-emodin combined with IFNγ (I-AE group) was better than that of IFN-γ group.

[0060] Both IDO and PD-L1 have been reported to inhibit CD4+ T cell proliferation, activation, and induce CD4+ T cell transformation into Treg. IDO catalyzes the conversion of tryptophan (an important essential amino acid) into different metabolites, resulting in tryptophan depletion. Since tryptophan is essential for T cell proliferation, tryptophan depletion switches the metabolic pathway from glycolysis to oxidative phosphorylation, leading to T cell stagnation [132-134]. Tryptophan metabolites (kynurenine, quinolinic acid, and picolinic acid) are toxic to CD4+ T cells. In addition, the tryptophan metabolite kynurenine can directly bind to AhR (aryl hydrocarbon receptor) to promote CD4+Foxp3+Treg differentiation [135,136]. PD-L1 secreted by MSCs binds to PD-1 and inhibits lymphocyte proliferation. PD-L1 can inhibit CD4+ T cell activation, reduce IL-2 secretion, silence T cells, and induce T cell death [137,138]. These factors can also inhibit AKT phosphorylation and upregulate Foxp3 expression, leading to the generation of Tregs[137,139]. We preliminarily verified the inhibitory effects of IDO and PD-L1 on CD4+ T cell activation.

[0061] As mentioned above, AE combined with IFN-γ can significantly increase the expression of IDO in UMSCs, both at the mRNA level and the protein level. In order to determine the signaling pathway of AE regulating IDO and guide the screening of more compounds with MSC regulatory effects, the changes in related molecular proteins were measured. First, the changes in protein levels related to cell apoptosis and autophagy were measured, and it was found that the change trend of p-ERK was consistent with that of IDO. We speculate that AE may increase the expression of IDO by reducing the p-ERK pathway. There are many literatures that mention that ERK is related to the differentiation of MSCs, and they all show that ERK is positively correlated with the differentiation ability of MSCs [140-142]. Therefore, the role of AE may be to inhibit MSC differentiation and promote its anti-inflammatory effect. However, no literature has been found to reveal whether the differentiation and anti-inflammatory effects of MSCs are mutually antagonistic. Instead, it is believed that MSCs mainly play the role of disease treatment through a combination of differentiation, anti-inflammatory, and paracrine effects. However, since the change trend of pERK is clear and repeatable, it will be confirmed by the p-ERK inhibitor PD98059. UMSCs were pretreated with PD98059 20um for 24h, and then pretreated with IFN-γ for 24h, and samples were collected. It was found that pretreatment with PD98059 20um for 24h can effectively inhibit p-ERK, but at the same time, it was found that the expression of IDO did not increase as a result. It was concluded that AE combined with IFN-γ can significantly increase the expression of IDO and is independent of P-ERK. Finally, combined with the upregulation of STAT1 after AE treatment, it is speculated that AE may promote the upregulation of immune regulatory molecules in MSCs through the classic STAT1 pathway. Example 5

[0062] Animals. SPF-grade C57BL / 6 mice weighing 20-25 g were used to establish the SAP model and purchased from the Experimental Animal Center of Sichuan University. All animal experiments in this project were approved by the Ethics Committee of Sichuan University.

[0063] Reagents: Caerulein, hematoxylin and eosin stain (Shanghai Yuanye Biotechnology Co., Ltd.), LPS, polyethyleneimine and Avidin-HRP (Sigma-Aldrich), FITC-CD11b (Thermo Fisher), Ly6G, Biotinauti-mouse TNF-α and TNF-α coating antibody (Beijing BIOLEGEND Biotechnology Co., Ltd.), anti-fluorescence aging mounting medium (containing DAPI) (Beijing Solebold Technology Co., Ltd.), neutral gum (Shanghai Specimen Model Factory, China), si-RNA (Shanghai Jima Pharmaceutical Co., Ltd.).

[0064] Establishment and treatment of acute pancreatitis model in mice. Healthy C57BL / 6 male mice were selected. They were deprived of food but not water for 12 hours before modeling. Preparation of caerulein (CAE): Prepared into a 1mg / ml stock solution with sterile saline. To avoid repeated freezing and thawing, it was divided and stored at -20℃. It was diluted with sterile saline to an appropriate concentration when used. Preparation of sodium pentobarbital: Prepared into a 1% concentration with water and stored at -20℃ for use. SAP modeling: Prepared into an appropriate concentration according to the weight of the mouse, and generally 200ul was administered intraperitoneally. The diluted caerulein was injected intraperitoneally 10 times, 60ug / kg / 1h. After the last administration of CAE, LPS 15mg / kg was injected intraperitoneally immediately. Treatment group: Immediately after modeling, the corresponding 1× 10^6 cells / kg cells were administered through the tail vein. All mice were given food after modeling. 24 hours after modeling, mice were anesthetized with an appropriate amount of 1% sodium pentobarbital, and then blood was collected from the eyeballs to collect plasma. Then, mice were killed by cervical dislocation to collect lung lavage fluid, lung tissue, pancreas and other samples required for experimental testing. Animal grouping: The mice were randomly divided into 4 groups, 3 mice in each group, namely: (1) NT group: normal control group, mice were not treated with any treatment; (2) SAP group: UMSCs without pretreatment; (3) IFN-UMSCs group: UMSCs were pretreated with IFN-γ5ng / ml for 24h; (4) I-AE-UMSCs group: UMSCs were pretreated with AE 20ug / ml combined with IFN-γ 5ng / ml for 24h.

[0065] Collection of pancreatic tissue and blood samples. Blood was collected from the eyeball and put into a 1.5 ml centrifuge tube with an appropriate amount of anticoagulant EDTA. The tube was allowed to stand at room temperature for 1 hour, centrifuged at 3000 rpm and 4°C for 10 min, and the upper serum was carefully drawn into another clean centrifuge tube. The tube was centrifuged at 13300 rpm for 10 min and 4°C, and the upper serum was drawn into another clean centrifuge tube and stored in a -80°C refrigerator. The mice were killed by dislocation of the neck, the abdominal cavity was opened, the pancreatic tissue was peeled off, and it was washed 3 times with cold PBS to remove excess fat tissue. The pancreatic tissue was divided into two parts, one part was fixed with 4% paraformaldehyde for HE staining, and the other part was embedded with OCT glue, and quickly frozen with liquid nitrogen and stored in a -80°C refrigerator for frozen sections and immunofluorescence staining. The chest cavity was opened, and the right lung was fixed in 4% paraformaldehyde for HE staining.

[0066] Immunofluorescence staining. The tissues embedded in OCT gel were trimmed to the appropriate size in the cryoprotectant and the tissue blocks were embedded in OCT gel on the base. Adjust the angle and slice 5-10um, with 2 to 3 samples on each slide. Then the steps are as follows: (1) Draw a circle around the tissue with an immunohistochemistry pen. (2) Add 50ul 4% paraformaldehyde and fix at room temperature for 10 minutes. (3) Rinse the tissue with 0.01M PBS for 5 minutes, discard, and repeat 3 times. (4) Punch: 0.5% Triton-PBS, 10 minutes. (5) Rinse with 0.01M PBS for 5 minutes, discard, and repeat 3 times. (6) Block with 5% BSA-PBS, pH 7.5, at room temperature for 30 minutes. (7) Dilute the primary antibody with an appropriate amount of PBS, add it dropwise to the tissue, and incubate overnight at 4℃. (8) Rinse with 0.01M PBS for 5 minutes, discard, and repeat 3 times. (9) Dilute the fluorescently labeled secondary antibody with an appropriate amount of PBS, add it to the tissue, and incubate at room temperature for 1 hour. (10) Soak in 0.01M PBS for 5 minutes, discard, and repeat 3 times. (11) Wash with water, add mounting solution (Solarbio-S2110) to the coverslip to seal (3~5ul), and seal with nail polish. (12) Take pictures with a fluorescence microscope.

[0067] Collection of mouse alveolar lavage fluid and determination of TNF-α. (1) After anesthesia, mice were killed by cervical dislocation, the chest cavity was opened to expose the lungs, and then a midline incision was made in the neck to expose and strip the trachea. (2) Carefully cut 1 / 2 of the trachea, and intubated with a prepared flat-blade needle. After insertion, thread the needle and tie a knot (so that the trachea and the needle fit tightly) to form a closed space for lavage; (3) Use a 1ml syringe to draw 1ml of sterile saline and inject it into the lungs through the needle in the trachea. Repeat the aspiration three times to obtain about 0.7ml of lung lavage fluid; (4) Centrifuge at 3000rpm, 5min, 4℃, and collect the supernatant and store it at -80℃ for later use (avoid repeated freezing and thawing). TNF-α in the lavage fluid was detected by ELISA.

[0068] CIITA gene silencing. a. Human UMSCs 10^5 cells / well were seeded in a 12-well plate and incubated overnight. b. Appropriate concentration of human oligo was mixed with double-free DMEM, the final volume was 50ul, and it was allowed to stand at room temperature for 5min. c. Appropriate mass of PEI was mixed with double-free DMEM, the final volume was 50ul, and it was allowed to stand at room temperature for 5min. d. Slowly add mixture c to mixture b, mix well, and let it stand at room temperature for 20min. e. Discard the cell culture medium, rinse with PBS 3 times, and replace with 400ul double-free DMEM. f. Slowly add mixture e to the cell culture medium, mix well, and place in the incubator for culture. g. After 6 hours, it was replaced with fresh complete culture medium, IFN-γ 5ng / ml was added, and culture was continued. h. After 24 hours, RT-qPCR was used to detect RNA silencing efficiency. Example 6

[0069] The SAP model of mice was established. The currently recognized methods for modeling acute pancreatitis in animals include retrograde pancreaticobiliary injection of 5% taurocholic acid, intraperitoneal injection of L-arginine, intraperitoneal injection of caerulein (CAE) combined with endotoxin (LPS), and supplementation of ethionine to cause choline deficiency. [149,150] CAE is a peptide homologue of cholecystokinin. When injected intraperitoneally in large doses for multiple times, it causes acute pancreatitis. This model is relatively stable and its mechanism of action is similar to that of human pancreatitis. It is the most commonly used SAP-induced model.

[150] . Literature Methods [151,152]Improvements were made, and the amylase activity in the serum of mice after modeling was used as an indicator to explore the appropriate number and concentration of CAE administration and the concentration of LPS. Finally, CAE was injected intraperitoneally 10 times in a row, one hour apart, at 60ug / kg each time, combined with an injection of 15mg / kg LPS immediately after the last CAE to successfully establish a mouse SAP model. After modeling, the mice were listless, ate less, drank less water, and had less activity. Mice were treated 24 hours after modeling, and the plasma amylase in the SAP group was more than three times that of the healthy control group ( Fig.11 A), indicating that the model was successfully established.

[0070] HE staining pathological scoring, including edema, inflammatory cell infiltration, and acinar cell necrosis, is an important basis for judging the severity of inflammation. Fig.11 As shown in B, the pancreas of mice in the normal group had a compact structure, without inflammatory cell infiltration and acinar cell necrosis. However, after modeling, pancreatic edema was observed in mice, and the interlobular spaces and acinar cell spaces were significantly enlarged. Inflammatory cell infiltration was observed in the tissue spaces, ducts, and lobules, accompanied by some acinar cell necrosis. The inflammatory cell infiltration was more obvious around the necrotic area. Pathological scores showed that the scores of the modeling group were significantly higher than those of the control group, including Edema (P<0.05), Inflammation (P<0.01), and Necrosis (P<0.05), indicating that the modeling method was feasible. We further verified the inhibitory effect of UMSCs on the activation of CD4+T cells by immunofluorescence staining. Fig.12 As shown, green is CD4+ and blue is cell nucleus DAPI. As can be seen from the figure, the main infiltrating inflammatory cells in the severe acute pancreatitis model are CD4+T cells.

[0071] UMSCs CIITA gene silencing. AE can upregulate UMSCs IDO and PD-L1 in vitro, so it is expected to improve the intervention effect of MSCs on SAP in vivo, but preliminary in vivo results show that the effect of I-AE-UMSCs group is not as good as that of I-UMSCs group. According to the literature, IFN-γ increases the expression of HAL-I and HAL-II in UMSCs, among which HAL-II mediates CD4+T cells and mainly plays an immune rejection role. Assuming that the UMSCs group pretreated with AE combined with IFN-γ upregulates HLA-II compared with the IFN-γ group, we can silence HLA-II by si-RNA. HLA class II proteins (HLA-HDP, HLA-HDQ and HLA-HDR) are heterodimers with polymorphism, α-chain and β-chain. Eliminating the expression of HLA-II does not require eliminating the expression of all individual HLA class II genes, but rather knocking out one of the transcription factors required for the expression of HLA class II genes. The HLA II gene has a conserved binding region. First, we determined the changes in CIITA in different groups of UMSCs, such as Fig.14 As shown in the figure, the expression of CIITA was indeed upregulated in the UMSCs group pretreated with AE combined with IFN-γ compared with the IFN-γ group, and we found that the increasing trend of CIITA was consistent with that of IDO. Therefore, we chose to silence CIITA in UMSCs.

[0072] In this experiment, we used transient transfection of si-RNA to silence the CIITA gene in UMSCs. First, the amount of transfection reagent (PEI) was screened using fluorescent FAM-oligo as a negative control, and the transfection rate after optimization reached more than 80%.

[0073] Changes of various inflammatory indicators after UMSCs intervention in SAP mice. Fig.15 As shown in A, the serum amylase concentration in the SAP group increased significantly, but decreased after the IFN-γ pretreatment UMCs group and the AE combined with IFN-γ pretreatment UMCs group; our SAP was given to untreated UMCs and found that untreated UMCs had no therapeutic effect. Compared with cells treated with IFN-γ alone, the AE combined with UMCs pretreatment group could better reduce the serum amylase level (P<0.01).

[0074] The results of pancreatic tissue HE staining and pathological scoring are as follows Fig.15As shown in B, the pancreatic pathological scores of the control group were low. After modeling, the pancreatic tissue structure was destroyed, a large number of inflammatory cells infiltrated, and the pathological scores increased. In the intervention group, although the UMSCs pretreated with IFN-γ could significantly reduce the pancreatic pathological scores, a small number of inflammatory cells were still infiltrated in the interlobular spaces and between the lobules, and the pancreatic tissue spaces were large; the pancreatic tissue of the AE combined with IFN-γ pretreatment group restored the pancreatic structure to a greater extent, with a compact tissue structure, almost no inflammatory cell infiltration in the interlobular spaces and between the lobules, and the scores were further reduced. The above results show that the pretreated cells can further reduce the aggravation of SAP.

[0075] HE staining and pathological scoring results of lung tissue are shown in Fig.16 As shown, microscopic observation showed that the lung tissue of the control group had no edema and no inflammatory cell infiltration, the lung tissue structure was clear, the alveolar wall was thin and the structure was intact; compared with the control group, the SAP group had obvious edema and consolidation in the lung tissue, which gradually worsened, with large areas of pulmonary consolidation, disappearance of the alveolar cavity, and a large number of inflammatory cells infiltrating; compared with the SAP group, the lung tissue edema of the UMSCs group pretreated with IFN-γ was weakened, and the inflammatory cell infiltration was reduced but still large; compared with the UMSCs group pretreated with IFN-γ, the lung tissue edema of the UMSCs group pretreated with AE combined with IFN-γ was further weakened, the inflammatory cell infiltration was reduced, and the alveolar wall was relatively intact.

[0076] At the same time, we performed lung lavage and collected lung lavage fluid for ELISA determination of the level of inflammatory factor TNF-α. Fig.17 B shows that compared with the SAP group, UMSCs treated with IFN-γ can reduce the level of inflammatory factor TNF-α (p<0.05); and the UMSCs group pretreated with AE combined with IFN-γ can further reduce the secretion of inflammatory cytokine TNF-α on this basis. From the results of lung tissue HE and lung lavage fluid TNF-α determination, it is shown that cells pretreated with AE combined with IFN-γ can further reduce SAP-related lung injury compared with cells pretreated with IFN-γ alone.

[0077] Changes in pancreatic infiltrating immune cells after UMSCs intervention in mice with SAP. It is necessary to study the molecular mechanism by which UMSCs inhibit the migration of inflammatory cells in pancreatitis. In order to verify the effect of UMSCs on immune cells, we performed immunofluorescence staining of pancreatic tissue. Fig.18 As shown in the figure, the SAP group had more CD4+T lymphocyte infiltration, and the CD4+T lymphocyte infiltration in the IFN group and the I-AE group was significantly reduced, indicating that the number of infiltrating CD4+T cells in the pancreatic tissue was improved.

[0078] By measuring mRNA and protein levels in vitro, we verified that AE combined with IFN-γ pretreatment can upregulate the immunosuppressive molecules IDO and PD-L1 of UMSCs, and proved in vitro that AE combined with IFN-γ can further enhance the immunosuppressive effect of UMSCs. In order to verify the intervention effect of pretreated UMSCs on SAP in mice, we first established a stable mouse SAP model by multiple intraperitoneal injections of high-dose caerulein (CAE) combined with lipopolysaccharide (LPS) according to the literature. After modeling, the serum amylase level, pancreatic tissue pathology score and pancreatic tissue immunofluorescence staining were measured to confirm that this mouse SAP modeling method is feasible and stable. The pretreated cells were used to treat SAP, and the effect was not ideal. It is speculated that the expression of HLA-II molecules may lead to immune rejection, which makes UMSCs play a pro-inflammatory role, so the silencing of the CIITA transcription gene in the HLA-II molecule was performed.

[0079] The silenced cells were used for pretreatment and then used for in vivo effect studies. The results of the detection of inflammatory pathological indicators showed that cells pretreated with AE combined with IFN-γ had better therapeutic effects, further reducing serum amylase levels, further reducing pancreatic inflammatory CD4+T cell infiltration and pancreatic tissue pathology scores, and further reducing lung tissue pathology scores and the expression of inflammatory cytokine TNF-α in the lungs. The results showed that UMSCs pretreated with AE combined with IFN-γ had a stronger immunosuppressive effect, not only significantly reducing pancreatic loss, but also significantly improving lung injury caused by SAP.

Claims

1. A therapeutic composition, characterized in that: the composition is isolated mesenchymal stem cells, such as human umbilical cord mesenchymal stem cells; the mesenchymal stem cells are pretreated with interferon combined with at least one active monomer derived from traditional Chinese medicine, such as rhamnolide (concentration range 5-100 μM), aloe rhamnolide (concentration range 5-200 μM), etc.; these compounds mainly regulate the immunomodulatory effect of mesenchymal stem cells through classical or non-classical interferon signaling pathways including JAK-STAT, ULK, mTOR, MAPK or SLFN proteins.

2. According to claim 1, wherein The isolated mesenchymal stem cells also include cultured mesenchymal stem cells.

3. According to claim 1, wherein The isolated mesenchymal stem cells also include genetically modified mesenchymal stem cells, such as mesenchymal stem cells whose antigen presentation-related molecules are interfered with by gene editing / silencing technology, so as to offset the enhancement of their immunogenicity caused by activating the interferon pathway.

4. According to claim 1, wherein The composition can also promote the immunomodulatory effect of mesenchymal stem cells by regulating the paracrine pathway, such as by promoting the secretion of extracellular vesicles carrying PD-L1.

5. The composition according to claim 1, further comprising a pharmaceutically acceptable carrier: the drug or molecule combined with IFNγ may be a free drug, or may be encapsulated in nanoparticles or liposomes, the material for preparing the nanoparticles may be polylactide-glycolide (PLGA), polylactic acid (PLA), polylysine (PLL) and albumin, etc.; the material of the liposome may be phospholipids and cholesterol, the phospholipids may be lecithin, soybean lecithin, cephalin, sphingomyelin, etc., or may be artificially synthesized phospholipids such as hydrogenated phosphatidylcholine (HSPC) with a lipophilic chain length of 18 carbons, distearoylphosphatidylethanolamine (DSPE), distearoylphosphatidylcholine (DSPC), and some other phospholipids with a lipophilic chain length of 16 carbons or 14 carbons.

6. According to claim 1, wherein The composition suppresses immune T cell populations.

7. According to claim 1, wherein The composition induces immunosuppression.